Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Health services and systems news

Show

From To
Few patients attend HIV clinic after ED visit for postexposure care

Only half of people who were referred to HIV clinics for follow-up after presenting to the emergency department for nonoccupational postexposure prophylaxis actually attended the clinic for care.

Published
23 hours ago
From
Healio
Bristol-Myers Squibb Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of Atazanavir Sulfate with Cobicistat for People Living with HIV-1

If approved, atazanavir sulfate and cobicistat could offer patients living with HIV-1 a single tablet that eliminates the need to take a boosting agent in a separate tablet. Cobicistat is developed by Gilead Sciences, Inc.

Published
23 hours ago
From
Bristol-Myers Squibb press release
London election candidates urged to tackle HIV as numbers in the capital continue to increase

A leading HIV charity is calling on London’s councillors and political groups to tackle the high rates of HIV in their boroughs and improve support services for the growing number of people living with HIV, in the lead up to May elections.

Published
15 April 2014
From
NAT press release
Viral hepatitis more deadly than HIV in Europe

Viral hepatitis, which includes hepatitis C virus (HCV) and hepatitis B virus (HBV), was blamed for nearly 90,000 deaths in 2010, while HIV claimed slightly more than 8,000 lives.

Published
14 April 2014
From
Science Daily
South Africa: ARV Programme Saves 780 000 Lives

South Africa's HIV antiretroviral treatment programme saved 780 000 lives between 2003 and 2012, according to a recently released independent review. But the tuberculosis programme is failing to meet targets.

Published
14 April 2014
From
Health-e
India: Govt HIV treatment programme completes 10 years

The anti-retroviral treatment (ART) covers 768,000 people but challenges in tackling the AIDS virus remain.

Published
11 April 2014
From
Live Mint
LGBT drugs and sexual health services needed in London

The strong association with high-risk sexual behaviour and sexual ill-health, including the transmission of HIV and hepatitis C, has highlighted the need for better links between sexual health and drug services. However, very few integrated services exist, and those that do are now only available to local residents due to recent changes in NHS commissioning.

Published
11 April 2014
From
The Guardian
International Liver Conference: activists demand affordable hepatitis C treatment

As the 49th International Liver Conference is officially starting, activist held a demonstration in the main hall to raise the issue of access to hepatitis C treatment in low and middle-income countries. Their protest targeted Gilead whose recently-approved direct-acting antiviral, Sovaldi, sells for USD $84,000.

Published
11 April 2014
From
HepCoalition
U.S. drug industry group defends price of Gilead hepatitis drug

The leading U.S. pharmaceutical industry trade group on Thursday defended the cost of Gilead Sciences Inc's new hepatitis C drug, Sovaldi, saying such treatments offer a priceless breakthrough for patients with the liver-destroying virus.

Published
11 April 2014
From
Reuters
Can we provide point-of-care viral load tests in poor countries?

It is not impossible to provide mobile, point-of-care viral load tests in resource-poor settings, the 2014 Treatment as Prevention workshop in Vancouver heard last week. By using a number

Published
10 April 2014
By
Gus Cairns
← First12345...420Next →

Filter by country